Under the auspices of the Progenitor Cell Biology Consortium (PCBC), our hub at Boston Children's Hospital used unbiased chemical screens in zebrafish and human induced Pluripotent Stem (iPS) Cells to identify two drugs that rescue the hematopoietic defects in Diamond Blackfan Anemia, a genetic bone marrow failure syndrome that lacks adequate pharmacologic or cell-based treatments. In the initial years of the next phase? the Progenitor Cell Translation Consortium?we propose to initiate clinical trials with these agents, and to establish a comprehensive center that during the subsequent years will develop new drugs, progenitor-based cell therapies, and gene therapies for additional genetic blood diseases, including Shwachman Diamond Syndrome, Fanconi Anemia, Dyskeratosis Congenita, primary immune deficiency, and hemoglobinopathy. We will build competency for both internal discovery and clinical translation, as well as Core facilities and generic platforms that will invite collaborations from external investigators, thereby serving the broader mission of the PCTC. Success in our aims will address considerable unmet needs for both the investigation of fundamental mechanisms of genetic blood disease and the development of novel therapeutics for conditions that while individually rare, are collectively a major challenge for hematology. The blood affords considerable advantages as a discovery system, given that analytic reagents and molecular catalogues of blood lineages abound; the high probability of success for blood diseases will establish a powerful proof-of-principle for leveraging human iPS cell models in clinical translation for other diseases.
Under the auspices of the Progenitor Cell Biology Consortium (PCBC), our hub at Boston Children's Hospital used unbiased chemical screens in zebrafish and human induced Pluripotent Stem Cells (iPS Cells) to identify two molecules that rescue defects in Diamond Blackfan Anemia (DBA), a genetic bone marrow failure syndrome that leads to anemia and disability in patients. Currently, treatment for DBA is inadequate, and new approaches are needed. In the initial years of the next phase of our project we propose to work within the Progenitor Cell Translation Consortium to initiate clinical trials of these novel agents, and to establish a comprehensive center that can discover new drugs, cell therapies, and gene therapies for a range of genetic blood diseases, including Shwachman Diamond Syndrome, Fanconi Anemia, Dyskeratosis Congenita, primary immune deficiency, and hemoglobinopathy. We will build competency for both internal discovery and clinical translation, as well as Core facilities and generic platforms, and will invite collaborations from external investigators, thereby serving the broader mission of the PCTC. Success in our aims will provide new insights into the mechanisms of genetic blood disease and lead to novel treatments for conditions that while individually rare, are collectively a major challenge for hematology.
| Vo, Linda T; Kinney, Melissa A; Liu, Xin et al. (2018) Regulation of embryonic haematopoietic multipotency by EZH1. Nature 553:506-510 |
| Rost, Megan S; Shestopalov, Ilya; Liu, Yang et al. (2018) Nfe2 is dispensable for early but required for adult thrombocyte formation and function in zebrafish. Blood Adv 2:3418-3427 |
| Lahvic, Jamie L; Ammerman, Michelle; Li, Pulin et al. (2018) Specific oxylipins enhance vertebrate hematopoiesis via the receptor GPR132. Proc Natl Acad Sci U S A 115:9252-9257 |
| Lummertz da Rocha, Edroaldo; Rowe, R Grant; Lundin, Vanessa et al. (2018) Reconstruction of complex single-cell trajectories using CellRouter. Nat Commun 9:892 |
| Wattrus, Samuel J; Zon, Leonard I (2018) Stem cell safe harbor: the hematopoietic stem cell niche in zebrafish. Blood Adv 2:3063-3069 |
| Sugimura, Ryohichi; Jha, Deepak Kumar; Han, Areum et al. (2017) Haematopoietic stem and progenitor cells from human pluripotent stem cells. Nature 545:432-438 |
| Blaser, Bradley W; Moore, Jessica L; Hagedorn, Elliott J et al. (2017) CXCR1 remodels the vascular niche to promote hematopoietic stem and progenitor cell engraftment. J Exp Med 214:1011-1027 |
| Henninger, Jonathan; Santoso, Buyung; Hans, Stefan et al. (2017) Corrigendum: Clonal fate mapping quantifies the number of haematopoietic stem cells that arise during development. Nat Cell Biol 19:142 |
| Wiley, D S; Redfield, S E; Zon, L I (2017) Chemical screening in zebrafish for novel biological and therapeutic discovery. Methods Cell Biol 138:651-679 |
| Volpi, Stefano; Yamazaki, Yasuhiro; Brauer, Patrick M et al. (2017) EXTL3 mutations cause skeletal dysplasia, immune deficiency, and developmental delay. J Exp Med 214:623-637 |
Showing the most recent 10 out of 15 publications
